Our Clinical-Stage Programs for more information. While we are advancing plans for an additional confirmatory Phase 3 clinical trial for roluperidone for the treatment of negative symptoms in schizophrenia, which we refer to as the C19 trial, in consultation with the FDA and expect to fund such trial and our resubmission of the NDA in part with net proceeds from our October 2025 private placement, there can be no assurances that we will successfully resubmit the NDA and obtain approval for rolup...
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001193125-26-101117 | EDGAR | 82K words |
| 2025-02-25 | 2024-12-31 | 0000950170-25-026055 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018392 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0000950170-23-006577 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001564590-22-007853 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001564590-21-011340 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001564590-20-009243 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001564590-19-007246 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005224 | EDGAR | — |
| 2017-03-13 | 2016-12-31 | 0001564590-17-004048 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-265685 | EDGAR | 20K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108840 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-069780 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0000950170-24-121063 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091195 | EDGAR | — |
| 2024-05-01 | 2024-03-31 | 0000950170-24-050883 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059747 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0000950170-23-036159 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021947 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023496 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015754 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0001564590-22-017670 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-06 | 0001193125-26-143986 | EDGAR | 1K words |
| 2026-04-02 | 0001193125-26-140148 | EDGAR | — |
| 2026-03-11 | 0001193125-26-101074 | EDGAR | — |
| 2026-02-03 | 0001193125-26-034538 | EDGAR | — |
| 2025-12-22 | 0001193125-25-328715 | EDGAR | — |
| 2025-11-19 | 0001193125-25-287048 | EDGAR | — |
| 2025-10-22 | 0001193125-25-245552 | EDGAR | — |
| 2025-03-19 | 0001193125-25-057901 | EDGAR | — |
| 2025-01-13 | 0001193125-25-005042 | EDGAR | — |
| 2024-12-05 | 0001193125-24-271652 | EDGAR | — |
204 total filings indexed. 172 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001598646 |
| Ticker | NERV |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | MA |
| Website | https://www.minervaneurosciences.com |
| Listed | 2014-07-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report